BEIGF:OTCMKTS
BeOne Medicines
$21.95
0.00%
(0.00) 1D
Jun 9, 12:49:46 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
42.40B
Avg. vol.
0.00
Volume
0.00
52-wk high
$24.92
52-wk low
$21.95
Beta
0.84
Shares outstanding
1.43B
No. of employees
12K
Mkt. cap
42.40B
Avg. vol.
0.00
Volume
0.00
52-wk high
$24.92
52-wk low
$21.95
Beta
0.84
Shares outstanding
1.43B
No. of employees
12K
News stories
From web sources and news partners
شبكة تواصل الإخبارية
·
9 minutes ago
S&P 500: Earnings strength offsets yield headwinds – HSBC | FXStreet
www.marketscreener.com
·
1 hour ago
Hong Kong Exchanges and Clearing : HKEX Launches S&P 500 & HKEX Tech 100 Index in Partnership with S&P Dow Jones Indices
TradingView
·
3 hours ago
SPX: S&P 500 Nears Record as Traders Gear Up for Earnings, Inflation Data
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com